Blavatnik Biomedical Accelerator: Deadline for Pre-Proposals (Spring)
December 10th, 2018 ~ 07:00pm - 07:00pm
Complete details of the Request for Proposals issued on August 3, 2018, can be found in the PDF posted on the Blavatnik Biomedical Accelerator's webpage for Harvard faculty:
Application timeline, Spring 2019 cycle
Application type: Development and Pilot applications
Pre-proposal due date: December 11, 2018
Announcement of finalists: February 2019
Full proposal due date: April 10, 2019
Announcement of awards: June 2019
Funding start date: July 1, 2019
Please note that applications are also being considered for the Fall 2018 cycle. The deadlines are earlier for those proposals. Complete details are listed in the PDF Request for Proposals document.
About the Blavatnik Biomedical Accelerator
The Blavatnik Biomedical Accelerator at Harvard University supports Harvard faculty in the performance and commercialization of applied life sciences research.
The Accelerator has provided $18.5 million in direct research support to 104 projects from across Harvard University targeting most major disease areas, including oncology, metabolic disease, diabetes, immuno-inflammatory disease, infectious diseases, and neurodegeneration. Supported projects have included therapeutics, diagnostics/biomarkers, instruments, and other biomedical technologies. Nearly half of all completed projects have been partnered with industry, through licenses to pharmaceutical, biotech, and startup firms (some launched from the Accelerator-supported technology) or via major industry-sponsored research agreements. These alliances have also led to $40 million in follow-on industry-sponsored research funding. The Accelerator is structured as a sustainable, “evergreen” program, with revenue from successfully launched technologies cycled back to support ongoing and future Accelerator projects.
The Accelerator and its funded projects are managed by the Office of Technology Development (OTD) under the auspices of the Office of the Provost, in consultation with an independent advisory committee comprising leaders from the Boston life science community.